본문으로 건너뛰기
저널
Cancer cell
코퍼스 내 활동 2024–2026
전체 논문 (63편 · 1/3)
-
Antigen-specific profiling identifies T-bet melanoma-specific CD8 T cells associated with response to neoadjuvant PD-1 blockade.
-
Axes of biological variation in diffuse large B cell lymphoma.
-
Myofibroblast programming blocks differentiation of TLS-organizing fibroblastic reticular cells in pancreatic cancer.
-
Reliable detection of Host-Microbe Signatures in cancer using PRISM.
-
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer.
-
Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest.
-
Fusobacterium, quiescent niches, and therapy response in colorectal cancer.
-
Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer.
-
Adaptive plasticity in targeted therapy.
-
Single-cell integration and multi-modal profiling reveals phenotypes and spatial organization of neutrophils in colorectal cancer.
-
Molecular insights into early malignant transition of hepatocellular carcinoma.
-
A snapshot of the earliest stages of hepatocellular carcinoma.
-
Candida albicans synergizes with Fusobacterium nucleatum in colorectal cancer progression via the Flo9-RadD interaction.
-
Framework for cancer evolution profiling and interception in colorectal cancer: ASCEND-CRC program.
-
A cross-kingdom alliance driving colorectal cancer.
-
TET2-mutant clonal hematopoiesis enhances macrophage antigen presentation and improves immune checkpoint therapy in solid tumors.
-
Mapping the inflammatory origins of lung cancer.
-
Armored macrophage-targeted CAR-T cells reset and reprogram the tumor microenvironment and control metastatic cancer growth.
-
Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma.
-
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.
-
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial.
-
Efficacy, safety, and biomarker analysis of datopotamab deruxtecan in advanced non-small cell lung cancer: ICARUS-LUNG01 phase 2 study.
-
Targeting internalization, resistance, and response: Insights from ICARUS-LUNG01.
-
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1 resistance mutation in NSCLC: The first-in-human phase 1 trial.
-
Decoding the spatial dynamics of tumor and immune cell interactions in solid cancers.
-
Cellular senescence in precancer lesions and early-stage cancers.
-
Epitranscriptomic control of cancer hallmarks: Functions, mechanisms, and therapeutics of RNA modifications.
-
Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.
-
Precision treatment with artificial intelligence assisted subtyping enhances therapeutic efficacy in HR+/HER2- breast cancer: The LINUXtrial.
-
Enhancing therapeutic outcomes with artificial intelligence for HR-positive, HER2-negative metastatic breast cancer.